Use this URL to cite or link to this record in EThOS:
Title: Microscale characterisation of a manufacturing route for lentiviral vectors
Author: Guy, H. M.
ISNI:       0000 0004 4692 0363
Awarding Body: University College London (University of London)
Current Institution: University College London (University of London)
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Lentiviral vectors used in clinical trials are currently produced by transient transfection of adherent human embryonic kidney (HEK)293(T) cells. However, this approach is not scalable and for commercialisation the development of alternative strategies based on suspension-adapted producer cell lines, that have all genes for vector production stably integrated, is desired. To assist progress in this area, the aim of this thesis was to establish a microscale cell culture platform that enables key bioprocess design data to be acquired rapidly and cost-effectively. ProSavin®, an equine infectious anaemia virus (EIAV)-derived lentiviral vector developed for the treatment of Parkinson’s disease (Palfi et al., 2014) was used as a model system. First, the suitability of a shaken 24-well plate system for the suspension culture of HEK293T-derived producer cells was established. This system was shown to support equivalent cell growth and ProSavin® titres to conventional shake flasks while providing substantially greater opportunity for parallelisation. Second, the utility of the microscale platform when combined with statistical Design of Experiments (DoE) techniques for optimising titres and informing the design of a scale-up strategy was demonstrated. An initial screening experiment identified three parameters as having a critical influence on ProSavin® titres, which were post-induction period, liquid fill volume and concentration of doxycycline (inducer compound). Subsequent optimisation experiments defined operating ranges for these parameters. Third, the insights obtained during the microwell investigations were shown to aid successful scale-up of the ProSavin® process to a single-use 2 L WAVE bioreactor. Fourth, with a view to informing further improvements in process design, the half-life of ProSavin® and other EIAV-based lentiviral vectors was determined, and approaches to moderate the rate of decay during upstream processing trialled. Overall, it was concluded that the microwell platform may be viewed as an effective tool for future use in the development of lentiviral vector bioprocesses.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available